Conference
Online Conference
October 15th – 16th, 2020
Registration is scheduled to open on August 31st, 2020.
Personalising Health Industry
For personalising health industry, it is essential to identify those factors that are critical for a transition towards business models supporting this approach, as it is in many respects fundamentally different from general practice today. In the interest of EU citizens, possible hurdles for health industry need to be identified that may impede the translation of scientific innovation into useful personalised products. An analysis along the value chain of personalised medicine development points to a high relevance of later stage aspects such as approval, provision and reimbursement as possible barriers. But also early stage aspects need consideration, like access to and sharing of population- as well as patient-specific biomedical-knowledge, differing requirements, culture and time-lines for the (co-)development of diagnostics and pharmaceuticals, as well as IP. In addition, access to financial resources for innovative new market entries as well as for established, but innovative SME shall be considered.
Recordings of the Conference can be found right here:
Programme
Day 1, October 15th
Conference moderated by Dr. Olaf Müller, Carus Consilium Sachsen GmbH
12.45
Check-in to online system & Introduction to the system
13.00
Host Greetings from the Free State of Saxony
Sebastian Gemkow, State Minister, Saxon State Ministry for Science, Culture and Tourism – Germany
13.05
Greetings from the European Commission
Jean-Luc Sanne, European Commission – Belgium
13.10
Introduction Regions4PerMed: the Project, Aim of the Conference
Gianni D’Errico, Toscana Life Sciences Foundation – Italy
Opening Session
13.20
Healthy Saxony – a Spotlight on Health Industry in Saxony
Dr. Olaf Müller, Healthy Saxony e.V. – Germany
13.30
Biosaxony – Supporting the Innovation Arena for Health Industry in Saxony
André Hofmann, Biosaxony e.V. – Germany
13.40
Key Note: Personalising Health Industry from an Educated Patient Perspective – a View on Hopes, Expectations, Hurdles
Prof. Joanne Hackett, BIOS Health – United Kingdom
14.00
Q&A
14.15
Short Break
Session I
Paving the Way: Infrastructures, R&D Approaches
14.30
Next Generation Biobanking – Biobanks as Potential Time Machines – a Vision for the Future
Prof. Michael Hummel, Charité Universitätsmedizin Berlin, German Biobank Node – Germany
14.45
Integration of Real-World Data in Healthcare
Mario Braga, Agenzia Regionale Sanità, Tuscany Region – Italy
15.00
The concept of N=1 trials: a Source of Deep Insight for Personalized Interventions?
Prof. Nicholas J. Schork, The Translational Genomics Research Institute (TGen), United States of America
15.15
Do we need to rethink Evidence Generation for Personalised Medicine?
Prof. Hans-Georg Eichler, European Medicines Agency (EMA) – The Netherlands
15.30
Q&A
15.50
Short Break
Session II
Setting the Scene: Aspects of Commercialisation, Product Strategies and Business Models
16.05
The Benefits and Challenges of Personalised Diagnostics
Jonathan Arnold, Qiagen – United States of America
16.20
Personalised Diagnostics as Driver for Personalised Medicine: a Synergistic Business Model
Dr. Norman Gerstner, Molecular Diagnostics Group – Germany
16.35
Personalized Medicine and Health – Challenges and Barriers from the Perspective of a Big Pharmaceutical Company
Giovanni Giuliani, Roche SpA – Italy
16.50
Personalised Medicine in Germany – Current Status and Outlook
Dr. Thorsten Ruppert, Verband forschender Arzneimittelhersteller e.V. (vfa) – Germany
17.05
Q&A
17.35
Wrap-up
End of Day One
Day 2, October 16th
Conference moderated by Dr. Olaf Müller, Carus Consilium Sachsen GmbH
09.00
Check-in to online system & Introduction to the system
09.15
Presentation Regions4PerMed: the Project, Aim of the Conference, Summarized Highlights of Day 1
Gianni D’Errico, Toscana Life Sciences Foundation – Italy
Session III
Making it real: Intellectual Property, Funding and Institutional Support
09.30
Challenges of Intellectual Property Protection in Personalised Medicine
Prof. Anne Lauber-Rönsberg and Dr. Sven Hetmank, Technical University Dresden – Germany
09.45
Good Translational Practice: a Supportive Environment for Innovative Life Sciences Companies
Dr. Siegfried Bialojan, EY – Germany
10.00
European Biotech-Clusters as Supporters of Translation
Anaïs le Corvec, Council of European BioRegions (CEBR) – Belgium
10.15
Q&A
10.35
Short Break
Session IV
Reaching the patient: Regulatory Aspects, Valorisation, Medical Societies, Patient Trust
10.50
Facilitating patient-led initiative with Industry – Patient Registry Data Access
Dr. Anna Ambrosini, Fondazione Telethon – Italy
11.05
Valorising Personalised Medicine and Therapeutics
Prof. Apostolos Tsiachristas, University of Oxford, HEcoPerMed – United Kingdom
11.20
Integrating Personalised Approaches into Guidelines in the Field of Oncology
Dr. Markus Follmann, MPH, MSc, Deutsche Krebsgesellschaft – Germany
11.35
Patient Education and Trust: Guidance and Support in an increasingly complex Therapeutic Setting – the Example of “Onkolotse”
Dr. Ralf Porzig, Sächsische Krebsgesellschaft e.V. – Germany
11.50
Q&A
12.10
Wrap-Up
End of the Conference
